Citi Downgrades Several Life Science Tools Vendors, Citing End Market Concerns | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citi Investment Research & Analysis today downgraded a number of life science tools firms saying end market weakness is expected to continue through 2012.

In a research report, analyst Amit Bhalla said the academic/government market will face pressure while pharma/biotech will see headwinds for the next year, limiting growth opportunities for tools vendors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.